Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: estudio Diana
| Autor: | Juan F. Ascaso, Juan Pedro-Botet, Vivencio Barrios, Jesús Millán, Adalberto Serrano, Xavier Pintó, Vicente Pascual, Aleix Cases |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Statin medicine.drug_class business.industry Type 2 Diabetes Mellitus Disease 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Diabetes mellitus medicine Pharmacology (medical) 030212 general & internal medicine Risk factor Family history medicine.symptom Cardiology and Cardiovascular Medicine Intensive care medicine business Mass screening Abdominal obesity |
| Zdroj: | Clínica e Investigación en Arteriosclerosis. 28:132-140 |
| ISSN: | 0214-9168 |
| Popis: | Objectives The aim of the present study was to develop a multidisciplinary consensus based on the Delphi system to establish clinical recommendations for the management of dyslipidaemia when hyperglycaemia is present, and the relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins. Methods The questionnaire developed by the scientific committee included four blocks of questions about dyslipidaemia in patients with impaired glucose metabolism. The results of the first two blocks are presented here: a) management of dyslipidaemia; b) relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins. Results Among the 497 experts who participated in the study, an agreement of over 90% was attained for recommending screening for dyslipidaemia in patients with diabetes or pre-diabetes and/or cardiovascular disease or a family history and/or abdominal obesity and/or hypertension. There was a high degree of agreement that a statin is the lipid-lowering treatment of choice, and that it should be switched when side effects develop. Also, the choice of statin and dose should be made according to baseline LDL cholesterol levels, the target to achieve, and the possible drug-drug interactions. Conclusions The screening of dyslipidaemia is primarily conducted in patients with cardiovascular disease, or any major cardiovascular risk factor. When prescribing a statin, physicians mainly focus on the ability to reduce LDL cholesterol and the risk of drug interactions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|